Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c, Slight Miss on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. AAPL
7. SPY
8. APLD
9. ORCL
10. USO

Go back to Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c, Slight Miss on Revenues

Capricor Therapeutics (CAPR) Says ALLSTAR Phase II Trial of CAP-1002 Showed Low Probability of Achieving Statistically-Significant Difference

May 12, 2017 6:45 AM EDT

Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that a pre-specified administrative interim analysis performed on six-month follow-up data from the ALLSTAR Trial, an ongoing randomized, double-blind, placebo-controlled, 142-patient Phase II clinical trial of CAP-1002 (allogeneic cardiosphere-derived cells) in adults who have experienced a large heart attack with residual cardiac dysfunction, has demonstrated a low probability (futility) of achieving a statistically-significant difference in the 12-month primary efficacy endpoint of percent change from baseline infarct size as a percent of left ventricular... More